Genmab PE Ratio 2019-2022 | GMAB
Current and historical p/e ratio for Genmab (GMAB) from 2019 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Genmab PE ratio as of January 27, 2023 is 31.70.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Genmab PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-01-27 |
38.87 |
|
35.02 |
| 2022-09-30 |
32.13 |
$1.11 |
28.95 |
| 2022-06-30 |
32.49 |
$0.92 |
35.32 |
| 2022-03-31 |
36.18 |
$1.77 |
20.44 |
| 2020-03-31 |
21.19 |
$2.42 |
8.76 |
| 2019-12-31 |
22.33 |
$2.53 |
8.83 |
| 2019-09-30 |
20.26 |
$2.40 |
8.44 |
| 2020-06-30 |
33.89 |
$1.22 |
27.78 |
| 2021-12-31 |
39.56 |
$0.73 |
54.19 |
| 2021-09-30 |
43.70 |
$0.70 |
62.43 |
| 2021-06-30 |
40.83 |
$0.62 |
65.85 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$25.514B |
$1.349B |
|
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
|
